A new malaria vaccine delivered through easy-to-use microneedle patches
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
This study is working on a new malaria vaccine that uses a protein from mosquito saliva and is delivered through easy-to-use microneedle patches, making it less painful and more convenient, especially for people in areas with limited resources.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | L2 Diagnostics, LLC NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11095978 on NIH RePORTER |
What this research studies
This research focuses on developing a malaria vaccine using a protein from the saliva of Anopheles gambiae mosquitoes, delivered via innovative microneedle patches. These patches are designed to be self-applied, minimizing pain and waste compared to traditional injections. The project aims to create a vaccine that can be stored at room temperature for up to six months, making it suitable for use in resource-limited settings. The ultimate goal is to prepare this vaccine for future clinical trials in humans after successful testing in mice.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals living in malaria-endemic regions who are at risk of malaria infection.
Not a fit: Patients who do not live in malaria-endemic areas or those who are not at risk for malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective and easily administered malaria vaccine, significantly reducing malaria infections in vulnerable populations.
How similar studies have performed: Other research has shown promise in developing vaccines using similar delivery methods, but this specific approach with AgTRIOVx is novel.
Where this research is happening
New Haven, United States
- L2 Diagnostics, LLC — New Haven, United States (Active)
Researchers
- Principal investigator: Anthony, Karen G. — L2 Diagnostics, LLC
- Study coordinator: Anthony, Karen G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.